title: Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients.
abstract: In the present study, we aimed to establish an additional standardized protocol with a higher H. pylori eradication rate in the remnant stomach. Fifty-five H. pylori-positive patients were randomly allocated to one of three regimens: LAC--lansoprazole, amoxicillin, and clarithromycin b.i.d. for 7 days (n = 17); LAC+CET--LAC b.i.d. plus cetraxate q.i.d. for 7 days (n = 20); and LEFT--LAC for 7 days in a horizontal body position on the left side for 30 min (n = 18). Patient compliance and side effects were checked via interviews. H. pylori eradication was successful in 75, 72, and 41% in LAC+CET, LEFT, and LAC, respectively. The eradication rate was significantly higher in LAC+CET than in LAC (P = 0.024) but not in LEFT (P = 0.058). Adverse events that occurred in each group were almost all mild ones. Cetraxate plus LAC for 1 week is a safe and effective regime for the eradication of H. pylori in patients after partial gastrectomy.
authors.affiliation: Department of Gastrointestinal Surgery, The University of Tokyo, Tokyo, Japan. kubotak-dis@h.u-tokyo.ac.jp
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kubota
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Shimizu
authors.forename: Koji
authors.initials: K
authors.lastname: Nozaki
authors.forename: Yutarou
authors.initials: Y
authors.lastname: Takeshita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ueda
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Imamura
authors.forename: Naoki
authors.initials: N
authors.lastname: Hiki
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Shouji
authors.initials: S
authors.lastname: Shimoyama
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: MaFune
authors.forename: Michio
authors.initials: M
authors.lastname: Kaminishi
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects; D018530:Gastric Stump; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000209:etiology; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D011187:Posture; D014148:Tranexamic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; C000665:cetraxate; D014148:Tranexamic Acid; D009853:Omeprazole